CASAMENTO CHARLES J has filed 16 insider transactions across 5 companies since March 2023.
Most recent transaction: a grant/award of 7757 shares of Eton Pharmaceuticals, Inc. ($ETON) on January 12, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 12, 2026 | Eton Pharmaceuticals, Inc. | $ETON | CASAMENTO CHARLES J | Director | A | Restricted Stock Units | 7757 | $0.00 | 302,928.0000 | 26,893,000 | 2.63% | 0.03% |
| Jan. 12, 2026 | Eton Pharmaceuticals, Inc. | $ETON | CASAMENTO CHARLES J | Director | A | Employee Stock Option (Right to Buy) | 12196 | $0.00 | 295,171.0000 | 26,893,000 | 4.31% | 0.05% |
| Dec. 12, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | CASAMENTO CHARLES J | Director | A | Stock Appreciation Rights | 164000 | $0.00 | 164,000.0000 | 33,191,622 | 9999.99% | 0.49% |
| Sept. 4, 2025 | GT Biopharma, Inc. | $GTBP | CASAMENTO CHARLES J | Director | A | Option to purchase Common Stock | 62500 | $0.00 | 62,500.0000 | 2,234,328 | 9999.99% | 2.80% |
| June 26, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | CASAMENTO CHARLES J | Director | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 30,408,890 | 9999.99% | 0.33% |
| Jan. 3, 2025 | Eton Pharmaceuticals, Inc. | $ETON | CASAMENTO CHARLES J | Director | A | Employee Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 25,895,086 | 9999.99% | 0.10% |
| Oct. 22, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | CASAMENTO CHARLES J | Director | G | Common Stock | 13000 | $0.00 | 0.0000 | 30,174,202 | 100.00% | 0.04% |
| Sept. 9, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | CASAMENTO CHARLES J | Director | P | Common Stock | 13000 | $2.56 | 13,000.0000 | 30,174,202 | 9999.99% | 0.04% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | CASAMENTO CHARLES J | Director | J | Stock Option (right to buy) | 20976 | $0.00 | 31,522.0000 | 30,132,170 | 39.96% | 0.07% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | CASAMENTO CHARLES J | Director | A | Stock Option (right to buy) | 20976 | $0.00 | 52,498.0000 | 30,132,170 | 66.54% | 0.07% |
| March 12, 2024 | Kuvatris Therapeutics, Inc. | $PXMD | CASAMENTO CHARLES J | Director | F | Common Stock | 992 | $0.69 | 2,386.0000 | 1,662,795 | 29.37% | 0.06% |
| Feb. 13, 2024 | Eton Pharmaceuticals, Inc. | $ETON | CASAMENTO CHARLES J | Director | A | Stock Option (Right to buy) | 30000 | $0.00 | 164,555.0000 | 25,645,366 | 22.30% | 0.12% |
| Jan. 29, 2024 | Kuvatris Therapeutics, Inc. | $PXMD | CASAMENTO CHARLES J | Director | F | Common Stock | 97 | $0.76 | 3,378.0000 | 1,662,795 | 2.79% | 0.01% |
| Jan. 2, 2024 | GridAI Technologies Corp. | $GRDX | CASAMENTO CHARLES J | Director | A | Common Stock | 19633 | $0.00 | 19,937.0000 | 336,342 | 6458.22% | 5.84% |
| June 16, 2023 | GT Biopharma, Inc. | $GTBP | CASAMENTO CHARLES J | Director | A | Option to purchase Common Stock | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| March 3, 2023 | Eton Pharmaceuticals, Inc. | $ETON | CASAMENTO CHARLES J | Director | A | Stock Option (Right to buy) | 25000 | $0.00 | 134,555.0000 | 25,146,000 | 22.82% | 0.10% |